Literature DB >> 15386666

Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data.

Adrian Bagust1, Sophie Beale.   

Abstract

Recent research has employed different analytical techniques to estimate the impact of the various long-term complications of type 2 diabetes on health-related utility and health status. However, limited patient numbers or lack of variety of patient experience has limited their power to discriminate between separate complications and grades of severity. In this study alternative statistical model forms were compared to investigate the influence of various factors on self-assessed health status and calculated utility scores, including the presence and severity of complications, and type of diabetes therapy. Responses to the EuroQol EQ-5D questionnaire from 4641 patients with type 2 diabetes in 5 European countries were analysed. Simple multiple regression analysis was used to model both visual analogue scale (VAS) scores and time trade-off index scores (TTO). Also, two complex models were developed for TTO analysis using a structure suggested by the EuroQol calculation algorithm. Both VAS and TTO models achieved greater explanatory power than in earlier studies. Relative weightings for individual complications differed between VAS and TTO scales, reflecting the strong influence of loss of mobility and severe pain in the EuroQol algorithm. Insulin-based therapy was uniformly associated with a detrimental effect equivalent to an additional moderate complication. Evidence was found that TTO values are not responsive in cases where 3 or more multiple complications are present, and therefore may underestimate utility loss for patients most adversely affected by complex chronic diseases like diabetes.

Entities:  

Mesh:

Year:  2005        PMID: 15386666     DOI: 10.1002/hec.910

Source DB:  PubMed          Journal:  Health Econ        ISSN: 1057-9230            Impact factor:   3.046


  68 in total

1.  Cost Effectiveness of IDegLira vs. Alternative Basal Insulin Intensification Therapies in Patients with Type 2 Diabetes Mellitus Uncontrolled on Basal Insulin in a UK Setting.

Authors:  Melanie J Davies; Divina Glah; Barrie Chubb; Gerasimos Konidaris; Phil McEwan
Journal:  Pharmacoeconomics       Date:  2016-09       Impact factor: 4.981

2.  Cost Effectiveness of Exenatide Once Weekly Versus Insulin Glargine and Liraglutide for the Treatment of Type 2 Diabetes Mellitus in Greece.

Authors:  Charalampos Tzanetakos; Alexandra Bargiota; Georgia Kourlaba; George Gourzoulidis; Nikos Maniadakis
Journal:  Clin Drug Investig       Date:  2018-01       Impact factor: 2.859

3.  A lifetime modelled economic evaluation comparing pioglitazone and rosiglitazone for the treatment of type 2 diabetes mellitus in the UK.

Authors:  Philip Home; Adrian Bagust; Matthew Taylor; Philip Ambery; Samara Mendes da Costa
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

Review 4.  A meta-analysis of health state valuations for people with diabetes: explaining the variation across methods and implications for economic evaluation.

Authors:  Tom W C Lung; Alison J Hayes; Andrew Hayen; Andrew Farmer; Philip M Clarke
Journal:  Qual Life Res       Date:  2011-04-07       Impact factor: 4.147

5.  A value set for the EQ-5D based on experienced health states: development and testing for the German population.

Authors:  Reiner Leidl; Peter Reitmeir
Journal:  Pharmacoeconomics       Date:  2011-06       Impact factor: 4.981

6.  The EQ-5D-5L index score is more discriminative than the EQ-5D-3L index score in diabetes patients.

Authors:  Chen-Wei Pan; Hong-Peng Sun; Xingzhi Wang; Qinghua Ma; Yong Xu; Nan Luo; Pei Wang
Journal:  Qual Life Res       Date:  2014-12-25       Impact factor: 4.147

Review 7.  A systematic review and critical assessment of health state utilities: weight change and type 2 diabetes mellitus.

Authors:  Scott Doyle; Andrew Lloyd; Lee Moore; Joshua Ray; Alastair Gray
Journal:  Pharmacoeconomics       Date:  2012-12-01       Impact factor: 4.981

8.  Potential risks and benefits of HIV treatment simplification: a simulation model of a proposed clinical trial.

Authors:  Bruce R Schackman; Callie A Scott; Paul E Sax; Elena Losina; Timothy J Wilkin; John E McKinnon; Susan Swindells; Milton C Weinstein; Kenneth A Freedberg
Journal:  Clin Infect Dis       Date:  2007-09-04       Impact factor: 9.079

9.  Preferences of patients with diabetes mellitus for inhaled versus injectable insulin regimens.

Authors:  Jeremy Chancellor; Samuel Aballéa; Alison Lawrence; Rob Sheldon; Sandrine Cure; Juliette Plun-Favreau; Nick Marchant
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

10.  Cost-effectiveness of pioglitazone in type 2 diabetes patients with a history of macrovascular disease: a German perspective.

Authors:  Werner A Scherbaum; Gordon Goodall; Katrina M Erny-Albrecht; Massimo Massi-Benedetti; Erland Erdmann; William J Valentine
Journal:  Cost Eff Resour Alloc       Date:  2009-05-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.